Market research
GNMK GenMark Diagnostics, Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 22.52
- Dividend yield
- 0.0%
- Beta
- 3.07
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 22.52
- Dividend yield
- 0.0%
- Beta
- 3.07
About
About GenMark Diagnostics, Inc
As of April 21, 2021, GenMark Diagnostics, Inc. operates as a subsidiary of Roche Holding AG.
Research context
GenMark Diagnostics, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the GNMK discussion.
5 years, 7 months ago
GenMark Diagnostics, Inc is currently in a long term uptrend where the price is trading 41.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.4.
GenMark Diagnostics, Inc's total revenue rose by 84.1% to $50M since the same quarter in the previous year.
Its net income has increased by 63.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.8% to $-10M since the same quarter in the previous year.
Based on the above factors, GenMark Diagnostics, Inc gets an overall score of 4/5.